Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC with Sintilimab and Donafenib for Unresectable HCC
NCT06244225Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and donafenib in hepatocellular carcinoma (HCC). Primary endpoint: Progression-Free Survival at 18 months. Started Jan 2024; status: recruiting.
02
Drugs
sintilimabdonafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06244225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244225.